Decellularized Human Placental Extracellular Matrix Tissue for Rotator Cuff Repair Augmentation

NCT ID: NCT07027735

Last Updated: 2025-12-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-31
• Study Completion Date: 2027-07-01

Brief Summary

The rotator cuff is a set of muscles and tendons that help move the shoulder. Tears in the rotator cuff are common, particularly as people age. Consequently, rotator cuff repair surgeries are common, as well. Despite the frequency with which rotator cuff repairs are performed, there remains a high rate of postoperative failure to heal. In such situations, there is a lack of connective tissue establishment between the rotator cuff tendon and the bone. One strategy to attempt to improve healing of the rotator cuff tendon back to the bone is via the use of extracellular matrix allograft. This treatment is composed of tissue from other humans, which is stripped of its cells so that just the scaffolding around the cells remains. This decellularized scaffolding can be placed at the rotator cuff healing site in an attempt to augment healing. Both animal studies and human studies have shown promise with this approach. Of those patients enrolling in the study, 50% will be assigned at random to receive a standard rotator cuff repair AND allograft treatment, while 50% will be assigned at random to receive standard rotator cuff repair WITHOUT allograft treatment. All patients enrolled in the study will also obtain an MRI at one year following surgery in order to assess tendon healing. Of note, one-year postoperative MRIs are not standard following rotator cuff repair - only those enrolled in the study will receive this MRI. There will be no financial consequence of receiving this MRI.

Detailed Description

Rotator cuff repair is one of the most commonly performed orthopedic surgeries, with over 450,000 surgeries performed every year in the United States. Unfortunately, the failure rate postoperatively remains unacceptably high despite advances in surgical techniques and rehabilitation strategies. Clinical studies have shown that only about half of repaired rotator cuffs heal by 12 months following surgery, with the rate of recurrent tears ranging from 20% in the best case and as high as 94% in certain patient populations with massive tears. Animal model studies indicate that the high failure rate after surgical repair is due to a lack of regeneration of the native tendon-to-bone transitional tissue. This native transition zone, the enthesis, is a functionally graded mineralized fibrocartilaginous structure that minimizes stress concentrations at the interface between the mechanically dissimilar tissues of tendon and bone. Rather than re-formation of this fibrocartilaginous transition, necessary for effective load transfer between tendon and bone, an abrupt transition of fibrovascular scar forms at the healing interface and the underlying bone resorbs. remodeling and are used to augment the body's natural healing response. The efficacy of decellularized ECM treatment in rotator cuff repair, specifically, has been demonstrated by animal studies, which have shown that decellularized ECM contributes to cell ingrowth, improved remodeling, and, ultimately, an improved repair as gauged by biomechanical testing. Similarly, human studies have also been promising. Decellularized ECM treatment was shown to both reduce retear rate and improve patient outcome scores when used in the treatment of large to massive rotator cuff tears in humans.

Connective tissue is the fibrous extracellular matrix (ECM) that provides the physical structure and support of the body's tissues. The efficacy of decellularized ECMs to augment damaged tissue and support tissue repair throughout the body (e.g. tendon, ligament, bone, mucosal, and integumental) has been well-documented in the literature. Decellularized ECMs contain ECM components to support tissue remodeling and are used to augment the body's natural healing response. The efficacy of decellularized ECM treatment in rotator cuff repair, specifically, has been demonstrated by animal studies, which have shown that decellularized ECM contributes to cell ingrowth, improved remodeling, and, ultimately, an improved repair as gauged by biomechanical testing. Similarly, human studies have also been promising. Decellularized ECM treatment was shown to both reduce retear rate and improve patient outcome scores when used in the treatment of large to massive rotator cuff tears in humans.

This is a single center prospective randomized controlled trial. Subjects will be recruited from patients seen by one of three participating shoulder and elbow surgeons at outpatient visits for their rotator cuff tear diagnosis at Columbia University Medical Center or any of the affiliated hospitals and/or outpatient office spaces. Adult patients (age 18 years or older) with a diagnosis of full thickness rotator cuff tear who meet operative criteria, including significant pain and weakness that have failed nonoperative management or arose from an acute injury, will be included in this study. Patients with partial thickness tears, full thickness subscapularis tears, Goutallier grade 3 and 4 fatty degeneration, and/or prior rotator cuff surgeries will be excluded from the study. Patients will receive preoperative clearance in accordance with current practices. Post-transplant patients will receive screening for infectious diseases, including HIV, HBV, and HCV, prior to surgery. Patients will be randomized via simple randomization into one of two groups - standard arthroscopic repair with decellularized ECM vs. standard arthroscopic repair without decellularized ECM. Patients will be seen postoperatively at 2 weeks, 3 months, 6 months, and 12 months. All patients will undergo comparable rehabilitation programs. An MRI will be performed at 12 months postoperatively. Any incidental MRI findings will be dealt with in accordance with standard practice. The primary outcome measure will be the postoperative retear rate, measured on one year postoperative MRI. Secondary outcome measures will both additional MRI measurements, including tendon structural continuity and tendon thickness, as well as patient reported outcomes, including Constant-Murley score, American Shoulder and Elbow Surgeons score, VAS Pain scores, and EQ-5D-5L. Patient reported outcomes will be collected at all patient visits.

Conditions

Rotator Cuff Tear

Keywords

rotator cuff tear

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment Arm

Standard Rotator Cuff Repair + Receives Allograft Treatment

Group Type: EXPERIMENTAL

Rotator Cuff Repair with Allograft Patch

Intervention Type: OTHER

Rotator cuff repairs will be augmented with use of a decellularized human placental allograft patch

Control Arm

Standard Rotator Cuff Repair + NO Allograft Treatment

Group Type: OTHER

Rotator Cuff Repair with No Augmentation

Intervention Type: OTHER

Standard rotator cuff repair with no augmentation

Interventions

Rotator Cuff Repair with Allograft Patch

Rotator cuff repairs will be augmented with use of a decellularized human placental allograft patch

Intervention Type: OTHER

Rotator Cuff Repair with No Augmentation

Standard rotator cuff repair with no augmentation

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Diagnosis of full thickness rotator cuff tear

Exclusion Criteria

• Partial thickness tears
• Full thickness subscapularis tears
• Goutallier grades 3 and 4
• Prior rotator cuff surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CTM Biomedical

INDUSTRY

Sponsor Role: collaborator

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

William Levine, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

NewYorkPresbyterian Hospital @ Columbia

New York, New York, United States

Countries

United States

Central Contacts

Andrew J Luzzi, MD

Role: CONTACT

Phone: 18604595700

Email: al3896@cumc.columbia.edu

Dawn Vega

Role: CONTACT

Email: dv2356@cumc.columbia.edu

Facility Contacts

Andrew Luzzi, MD

Role: primary

Other Identifiers

AAAV5510

Identifier Type: -

Identifier Source: org_study_id